In a welcome return to face-to-face events, the probiotic specialists said all would be revealed at Vitafoods Europe, in Geneva Palexpo, from 5-7 October 2021.
“The supplementation with Lacticaseibacillus rhamnosus HA-114 could favour wellness and facilitate adherence during a diet-based weight reduction program,” says Morgane Maillard, Marketing Group Manager at Lallemand.
“The probiotic improved self-control behaviours which could lead to a better long-term adherence to dietary recommendations and higher loss.
“This is a very innovative approach for the weight management market,” she adds. “We have submitted a patent leveraging the results of this breakthrough clinical study.”
Whilst L. rhamnosus HA-114 has been implicated in weight management, the randomised, double-blind, placebo-controlled trial focuses on the probiotic’s effect on eating behaviours such as self-control/hunger, binge eating and food cravings.
Enrolling 152 overweight participants on a diet, the study uses questionnaires to not only reveal its benefits to weight control but also its influence on improving perceived stress and other mood-related behaviours.
The study will also show the strain’s effect on metabolic markers such as insulin, HOMA-IR, LDL-cholesterol, and triglycerides.
Lallemand are also set to reveal details of two separate collaborations with FrieslandCampina Ingredients and Activ’Inside.
In the first pact, FrieslandCampina Ingredients and Lallemand will introduce two ready-to-market products targeting gut health that bring together best-in-class prebiotics and probiotics.
The first product, PRO-Digest Health Shot made from clinically documented prebiotics Biotis Galacto-oligosaccharides (GOS) and B. lactis LAFTI B94, supports a healthy microflora, reinforces gut barrier integrity, and helps to relieve occasional abdominal discomfort, such as bloating and constipation.
The second product, PRO-Digest Bowel Support is a formula made from Biotis GOS and L. paracasei HA-196, designed to alleviate discomfort and improve the day-to-day symptoms of consumers with digestive health issues, with clinical proof to improve frequency of bowel movements in healthy adults with irritable bowel syndrome (IBS)-like symptoms.
“The partnership was propelled by the growing popularity of the synbiotic category which went from 48% in 2017 to 54% in 2020 (% of probiotics containing prebiotics in their formulation),” explains Maillard.
“Also, the gut health category is still going strong, with 47% of global consumers finding digestive health products appealing and 68% of consumers recognising the link between digestive health and overall health.”
Lallemand and Activ’Inside pact
Maillard goes on to explain the motivations behind Lallemand’s agreement with Activ’Inside, which looks to combine the saffron extract Safr’inside and psychobiotic Cerebiome to support mental wellness.
“This patented combination with validated compatibility and health claims and offers a good synergistic action on bioavailability,” adds Maillard.
“The combination has an identified mechanism of action and a quick action effect which translates into a high level of consumer satisfaction. It is a unique formula for targeting the gut-brain axis for mood-balance.”
Lallemand Health Solutions will be at booth #F40 at Vitafoods Europe, in Geneva Palexpo, from 5-7 October 2021.